| abstract |
Disclosed herein is a method of enhancing antibody-dependent cellular cytotoxicity (ADCC) in a subject comprising administering to a subject in need thereof a therapeutically effective amount of an anti-BCMA antibody and an effective amount of an antibody-coupled T cell receptor (ACTR ) T lymphocytes and/or NK cells of a construct which may comprise an extracellular domain with affinity and specificity for the Fc portion of an immunoglobulin molecule (Ig); a transmembrane domain; optionally a or multiple co-stimulatory domains, and a cytoplasmic signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM). |